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Abstract
Activation of hepatic stellate cells (HSCs) plays a crucial role in liver fibrogenesis. armepavine (Arm,
C19H23O3N), an active compound from Nelumbo nucifera, has been shown to exert
immunosuppressive effects on T lymphocytes and on lupus nephritic mice. The aim of this study
was to investigate whether Arm could exert anti-hepatic fibrogenic effects in vitro and in vivo. A cell
line of rat HSCs (HSC-T6) was stimulated with tumor necrosis factor-α (TNF-α) or
lipopolysaccharide (LPS) to evaluate the inhibitory effects of Arm. An in vivo therapeutic study was
conducted in bile duct-ligated (BDL) rats. BDL rats were given Arm (3 or 10 mg/kg) by gavage twice
daily for 3 weeks starting from the onset of BDL. Liver sections were taken for fibrosis scoring,
immuno-fluorescence staining and quantitative real-time mRNA measurements. In vitro, Arm (1-10
μM) concentration-dependently attenuated TNF-α- and LPS-stimulated α-SMA protein expression
and AP-1 activation by HSC-T6 cells without adverse cytotoxicity. Arm also suppressed TNF-α-
induced collagen collagen deposition, NFκB activation and MAPK (p38, ERK1/2, and JNK)
phosphorylations. In vivo, Arm treatment significantly reduced plasma AST and ALT levels, hepatic
α-SMA expression and collagen contents, and fibrosis scores of BDL rats as compared with vehicle
treatment. Moreover, Arm attenuated the mRNA expression levels of col 1α2, TGF-β1, TIMP-1,
ICAM-1, iNOS, and IL-6 genes, but up-regulated metallothionein genes. Our study results showed that
Arm exerted both in vitro and in vivo antifibrotic effects in rats, possibly through anti-NF-κB
activation pathways.
Background
Liver fibrosis is a wound-healing response to various
chronic liver injuries, including alcoholism, persistent
viral and helminthic infections, and hereditary metal
overload [1,2]. Activation of hepatic stellate cells (HSCs)
plays a crucial role in the development of liver fibrosis [1-
5]. During the activation process, HSCs undergo pheno-
type transformation from vitamin-A-storing quiescent
cells to myofibroblast-like activated cells [1-4]. Activated
HSCs are proliferative and fibrogenic, with accumulation
of extracellular matrix (ECM), including type I collagen.
Prolonged liver injury and inflammation result in hepato-
cyte damage, which triggers activation of HSCs and
recruitment of inflammatory cells such as macrophages
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into the liver by paracrine secretion of cytokines [1,2]. Fur-
thermore, activated HSCs have been implicated in hepatic
inflammation through their ability to secrete cytokines
and chemokines, and express adhesion molecules [1-4].
NFκB is an essential regulator of the expression of a
number of genes involved in immune, inflammatory, and
growth responses [6-8]. In most cells under normal con-
ditions, NFκB exists in a latent state in the cytosol and is
bound to inhibitory proteins including IκBα that mask a
nuclear localization signal. Cytokines such as TNF-α acti-
vate NFκB signaling via the activation of the IκB-kinase
(IKK) complex and subsequently phosphorylate and
thereby degrade the IκBα protein, releasing the cytosolic
dimer p65-p50 to translocate into the nucleus to activate
transcription of various genes including inducible nitric
oxide synthase (iNOS) and intercellular adhension molecule
(ICAM)-1 [6-8]. Several in vitro studies showed that DNA
binding activity of NFκB is demonstrated in activated but
not in quiescent HSCs, and activation of HSCs is associ-
ated with the nuclear translocation of NFκB [9,10]. These
observations provide functional support for a critical role
of NFκB in the activation of HSCs.
Nelumbo nucifera is a common edible and medicinal plant
used in Asia for the treatment of diarrhea, bleeding, fever,
and infection [11-13]. Extracts from Nelumbo nucifera
have been shown to exert antioxidant or free radical scav-
enging activities [12,14,15]. Armepavine (Arm,
C19H23O3N), an active compound from Nelumbo nucifera,
has been shown to exert not only anti-inflammatory
effects on human peripheral blood mononuclear cells
[16,17], but also immunosuppressive effects on T lym-
phocytes and on lupus nephritic mice [13]. In addition,
Arm has been reported to induce apoptosis in leukemia
cells [18]. However, the potential of Arm as an agent
against hepatic fibrosis and its mechanisms of action
remain to be clarified. Recently, we have reported that
fibrosis-related gene transcripts were induced in the liver
of BDL rats [19,20], and the TNF-α related signaling path-
way in HSCs could be a therapeutic target. [21,22]. In the
present study, we investigated the in vitro effects of Arm on
TNF-α-induced NFκB activation in HSCs and in vivo anti-
fibrotic effects in BDL rats.
Methods
Armepavine (Arm) solution and chemicals
Arm was obtained from Dr. Chien-Chang Shen (NRICM,
Taiwan, ROC), according to the preparation procedures
published before [13,23]. Armepavine synthesized by our
method was a racemate with a purity of >95% and was
confirmed by NMR analysis. Its NMR spectra were identi-
cal with those of (S)-armepavine. This synthesis has been
repeated several times and gave the same results. For in
vitro experiments, Arm was dissolved in dimethyl sulfox-
ide (DMSO) and diluted with medium to give a DMSO
concentration below 0.1%. For in vivo experiments, Arm
was mixed with 0.7% carboxyl methyl cellulose (CMC).
Silymarin and other chemicals were from Sigma Chemical
Co (St. Louis, MO, USA). Silymarin was also mixed with
0.7% CMC for in vivo administration.
HSC-T6 cell line
The HSC-T6 cell line, a generous gift of Prof. S.L. Fried-
man, is an immortalized rat HSCs which are transfected
by the large T-antigen of SV40 vector containing a Rous
sarcoma virus promoter [24]. Bioassays of HSC-T6 activa-
tion have been previously established and reported by our
group [21,22]. HSC-T6 cells were maintained in Way-
mouth's medium (containing 10% FBS, pH 7.0) at 37°C
in 5% CO2/95% air. 90% confluent monolayer of HSCs
were passaged by trypinization and HSCs were plated in
75T culture flask at a number of 1 × 106 cells per flask in
Waymouth's medium containing 10% FBS and incubated
under 5% CO2 in air at 37°C.
Evaluation of cytotoxicity of Arm in HSCs
The potential of cytotoxicity of Arm was assessed by the
MTT assay. Briefly, HSCs were incubated in 24-well plates
containing Waymouth's MB752/1 medium (FBS-free)
with or without Arm at different concentrations for 24 hrs
at 37°C, with addition of minimum essential medium
containing 0.1 mg/ml MTT in the last hour. After discard-
ing medium, the formazan particle was dissolved with
DMSO. The extent of reduction of 3-(4,5-dimethylthia-
zol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) to for-
mazan within cells was quantitated by measuring optical
density at 540 nm by using enzyme-linked immunosorb-
ent assay reader [22,25].
Luciferase assays in transiently transfected HSCs
105 cells/well were seeded on 24-well plates the day before
transfection. Plasmid NFκB-Luc and AP-1-Luc (1 μg/well)
(Strategene, La Jolla, CA) and pRL-SV40 (0.2 μg/well)
(Promega, Madison. USA) were transfected into cells by
Fugene 6 (Roche, Indianapolis, IN, USA). The pNFκB-Luc
and the pAP-1-Luc consist of NFκB and AP-1 binding
regions. Plasmid pRL-SV40 served as an internal control
to normalize the transfection efficiency. After treatment
with TNF-α, LPS or drugs for 24 hrs in 5% CO2 incubator
at 37°C, cells were harvested and lysed in 100 μl of lysis
reagent. 20 μl of cell lysate was then mixed with 100 μl of
luciferin before luminescence detection. The intensity of
luciferase activity was measured with AutoLumat LB953
(Berthold technologies, Bad Wildbad, Germany). The
luciferase assay kits were purchased from Promega (Mad-
ison. USA) [21,22].Journal of Biomedical Science 2009, 16:78 http://www.jbiomedsci.com/content/16/1/78
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Western blot analyses
In brief, cytoplasmic and nuclear extracts of HSCs were
prepared by washing ice-cold PBS twice. Then 100-μl lysis
buffer A (10-mM HEPES, 10-mM KCl, 0.1-mM EDTA, 1-
mM dithiothreitol (DTT), 0.5-mM phenylmethanesulfo-
nyl fluoride (PMSF) in distilled water) was added into
each dish with incubation on ice for 10 min. Cell lysates
were collected into 1.5-ml tubes and were centrifuged at
15,000 × g, 4°C, 20 min. The supernatant (protein of cyto-
plasm) and lysate (protein of nucleus) were collected and
50-μl lysis buffer B (20-mM HEPES, 0.4-M NaCl, 25%
glycerol, 1-mM EDTA, 1-mM DTT, 0.5-mM PMSF in dis-
tilled water) was added into the lysate of nucleus protein.
The cell suspension was votexed for 10 seconds and were
allowed to gently agitate for 30 min at 4°C and then cen-
trifuged at 15,000 × g for 10 min at 4°C. The supernatant,
containing the nuclear extract fraction, was transferred to
a fresh 1.5-ml tube for NFκB translocation assay. Fifty μg
of proteins each of cytoplasmic fraction from buffer A and
nuclear fraction from buffer B were separated on a 10%
SDS-PAGE and transferred onto Immobilon-PVDF (Milli-
pore, Bedford, MA, USA) in a transfer buffer (6.2 mM
boric acid, pH 8.0). Blots were incubated initially with
blocking buffer (5% BSA) for 1 hour at room temperature,
and then with specific primary antibodies against mouse
pIκBα, mouse α-SMA, mouse α-tubulin, mouse p65 and
mouse PCNA (Santa Cruz Biotechnology, Santa Cruz,
California, CA, USA); and mitogen-activated protein
kinase (MAPK) phosphorylation levels were determined
by specific primary antibodies against p38, extracellular
signal-regulated kinase (ERK)1/2 and c-jun N-terminal
kinas (JNK) 1/2 (Cell Signaling Inc, USA). β-Actin was
used as an internal control for equal protein loading. The
protocols of our previous studies [26] were followed to
measure phosphorylation of ERK, p38 MAPK, and JNK.
Primary antibodies had been diluted (1:10000) with Tris-
buffered saline-Tween 20 (TBS-T) containing 1% non-fat
milk. After primary antibody incubation, the blots were
washed with TBS-T for 1 hr and incubated with specific
second antibody conjugated with horseradish peroxidase
(Becton Dickinson, Franklin Lakes, NJ, USA) for 1 hr at
room temperature. After the washing of the secondary
antibodies (1:2000) with TBS-T, immunodetection was
performed, using an enhanced chemiluminescence kit for
Western blot detection (Amersham Pharmacia Biotech,
Buckinghamshire, U.K.). Film exposure ranged from a few
seconds to 5 min.
Quantification of collagen deposition by cultured HSCs
HSCs (in serum-free medium) were co-treated with TNF-
α (10 ng/ml) and armepavine for 24 hrs. Cells were
washed and collagen deposited in the wells was assayed
using the Sircol collagen assay kit (Biocolor, Belfast, Noth-
ern Ireland) according to the manufacturer's instructions
[21]. The Sircol dye-collagen complex was dissolved in
0.5% sodium hydroxide after wash twice with ethanol.
Collagen was quantitated by spectrophotometry at 540
nm and results were expressed as percentage of the
untreated controls.
Hepato-fibrotic rats
Hepatic fibrosis was induced by bile duct ligation (BDL)
in male Sprague-Dawley rats (250~300 g) and we have
recently documented changes in molecular and cell bio-
logical parameters related to fibrosis in these rats [19,20].
A double ligation of the bile duct was performed in rats
under anesthesia by a proximal ligature around the bile
duct in the hilus of the liver and by a distal ligature close
to its entry into the duodenum. A cut was then made
between ligatures. On sham-operated rats, the bile duct
was mobilized but not ligated. Rats were maintained on a
standard rat pellet diet and tap water ad libitum. Animal
studies were approved by the Animal Experiment Com-
mittee of the University and conducted humanely, in
accordance with the Guide for the Care and Use of Labora-
tory Animals (National Academic Press, USA, 1996). There
were five groups of rats: (a) control rats receiving 0.7%
CMC, (b) BDL rats receiving 0.7% CMC, (c) BDL rats
receiving silymarin (50 mg/kg, mixed with 0.7% CMC),
(d) BDL rats receiving Arm (3 mg/kg), and (e) BDL rats
receiving Arm (10 mg/kg). Arm or silymarin was given by
gavage twice daily for 3 weeks starting from the onset of
BDL. Three weeks after bile duct ligation or sham opera-
tion, the rats were examined for the parameters listed
below. On the day of measurement, venous blood was
withdrawn from each rat under anesthesia, and thereafter
the rat was sacrificed by KCl injection to remove the liver
for homogenization and biochemical analysis.
Biochemical analysis of plasma
Blood samples were collected (6 ml each from the femoral
vein) and immediately centrifuged at 1300 g at 4°C, and
plasma samples were kept at -80°C for liver and renal
function tests. Alanine transaminase (ALT) and aspartate
transaminase (AST) activities were measured using a
colorimetric analyzer (Dri-Chem 3000, Fuji Photo Film
Co, Tokyo, Japan), as we described previously [22].
Histological examination
For morphometric studies, the liver fragments were taken
from the left lobe of each rat. Liver specimens were pre-
served in 4% buffered paraformaldehyde and dehydrated
in a graded alcohol series. Following xylene treatment, the
specimens were embedded in paraffin blocks, cut into 5-
μm thick sections and placed on glass slides. The sections
were then stained with picro-sirius red for collagen distri-
bution [27]. A numerical scoring system for histologically
assessing the extent of fibrosis was adapted from the for-
mula of Scheuer [28], with minor modifications [29].Journal of Biomedical Science 2009, 16:78 http://www.jbiomedsci.com/content/16/1/78
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Briefly, fibrosis was graded as: 0: no fibrosis; grade 1:
enlarged, fibrous portal tracts; grade 2: periportal or por-
tal-portal septa, but intact architecture; grade 3: fibrosis
with architectural distortion; grade 4: probable or definite
cirrhosis. Additionally, hepatocyte necrosis or degenera-
tion severity was also graded as: 0, no hepatocyte necrosis
or degeneration; grade 1, focal necrosis or degeneration of
hepatocytes (mild, lesion no. 3); grade 2, multifocal
necrosis or degeneration of hepatocytes (moderate, lesion
no.> 3); grade 3, locally extensive or diffuse necrosis or
degeneration of hepatocytes (severe). Hepatocyte degen-
eration is mainly associated with cytoplasmic vacuolation
and swelling, with the nuclear contour generally intact,
whereas hepatocyte necrosis is associated with karyopyk-
nosis (nuclear shrinkage) and karyorrhexis (nuclear rup-
ture), in addition to degenerative changes. The liver
scoring examination was performed by the pathologist
(Y.-T. C.) who was blinded to rats' treatment assignment.
Fibrosis scores were given after the pathologist had exam-
ined throughout three different areas in the tissue slide for
each rat.
Quantification of collagen deposition in the livers of BDL 
rats
A portion of liver tissue was homogenized in acetic acid
(0.5 M) at 4°C using an ULTRA TURRAX® homogenizer
(Ika Labotechnik, Staufen, Germany). The fraction of
insoluble collagen after acid extraction, composed of
cross-linked collagen, was then heated at 80°C for 60 min
for conversion into soluble gelatin. The gelatin contents of
the acid extracts were assayed using the Sircol collagen
assay kit according to the manufacturer's instructions and
the method described previously [21,29].
Quantitative real-time PCR for the analysis of gene 
transcripts
Total RNA was isolated from hepatic tissues by the
method of Chomczynski and Sacchi [30]. For cDNA syn-
thesis, 1 μg of total RNA was reverse-transcribed in a 30 μl
of reaction mixture containing 10 μM dNTP mix, 500 μg/
μl oligo(dT)12-18, 0.2 μM DTT, 40 units of RNase inhibi-
tor, 200 units of M-MLV reverse transcriptase, and 5 ×
buffer (1.5 mM MgCl2) (Invitrogen, Carlsbad, CA, USA).
The reaction mix was incubated at 37°C for 60 min and
then denatured at 65°C for 10 min. Quantitative PCR
analysis was performed using an ABI prism 7900 HT
Sequence Detection System (Applied Biosystems, Foster
City, CA, USA). In the study, we used two different meth-
ods of quantitative PCR [20-22]: (I) SyBR Green method
for the expressions of G3PDH, ICAM-1, TGF-β1, and α-
SMA genes. SyBR Green, a double-stranded DNA binding
dye, was used for the fluorescent detection of DNA gener-
ated during the PCR. The PCR reaction was performed in
a total volume of 20 μl with 0.4 pmol/μl of each primer,
and 2 × SyBR Green PCR master mix (Applied Biosys-
tems); 1 μl cDNA corresponding to 100 ng of total RNA
was used as template. The primer sequences for PCR
amplification (α-SMA forward primer: 5'-TTC GTT ACT
ACT GCT GAG CGT GAG A-3', reverse primer: 5'-AAA
GAT GGC TGG AAG AGG GTC-3'; TGF-β1  forward
primer: 5'-TAT AGC AAC AAT TCC TGG CG-3', reverse
primer: 5'-TGC TGT CAC AGG AGC AGTG-3'; G3PDH for-
ward primer: 5'-AGC CCA GAA CAT CAT CCC TG-3',
reverse primer: 5'-CAC CAC CTT CTT GAT GTC ATC-3')
were according to our previous reports [20-22]. The prim-
ers of ICAM-1 (forward primer: 5'-CAC TAG AGG AGT
GAG CAG GTT AAC AT-3', reverse primer: 5'-TAT GAC
TCG TGA AAG AAA TCA GCT CTT-3') were designed
according to the published sequence of rat ICAM-1
(D00913) for PCR amplification. (II) The Taqman® PCR
Core reagent kit (PE Applied Biosystems) was used
according to the manufacturer's protocol for the expres-
sions of procollagen I (col 1α2), tissue inhibitor of metallopro-
teinase-1 (TIMP-1), iNOS, interleukin (IL)-6 and
metallothionein genes. Specific primers and probe for pro-
collagen I (col 1α2), tissue inhibitor of metalloproteinase-1
(TIMP-1), iNOS, interleukin (IL)-6 and  metallothionein
genes were synthesized by PE Applied Biosystems. For
each sample tested, PCR reaction was carried out in a 50-
μl volume containing 1 μl of cDNA reaction (equivalent
to 50 ng of template RNA) and 2.5 units of AmpliTaq
Gold. Oligonucleotide primers and fluorogenic probe
were added to a final concentration of 100 nM each. The
amplification step consisted of 60 cycles of 94°C for 45 s,
58°C for 45 s, and 65°C for 1 min.
Data analysis
Data are expressed as the mean ± SEM. One-way analysis
of variance (ANOVA) was used for comparison of bio-
chemical and molecular parameters. Statistical signifi-
cance was accepted at p < 0.05. A non-parametric method
(the Dunn procedure under the Kruskal-Wallis test) was
used for multiple pairwise comparisons between groups
for the histological grades of fibrosis. Statistical signifi-
cance was accepted at p < 0.05.
Results
In vitro effects of Arm on HSC-T6 cells
Effects of Arm on TNF-α-induced collagen deposition in HSCs
As shown in Figure 1a, TNF-α (10 ng/ml) stimulated col-
lagen deposition in HSC-T6 cells to 143 ± 9% of the un-
stimulated, control level, which was concentration-
dependently reduced by Arm (1 - 10 μM). Significant inhi-
bition was observed at 10 μM (to 90 ± 2% of control
level).
Effects of Arm on TNF-α- and LPS-induced α-SMA expression in 
HSCs
TNF-α (10 ng/ml) stimulated α-SMA secretion (to 274 ±
34% of control level) in HSC-T6 cells. Both N-acetyl-Journal of Biomedical Science 2009, 16:78 http://www.jbiomedsci.com/content/16/1/78
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(a) Effects of armepavine on collagen deposition by HSC-T6 cells after TNF-α stimulation for 24 hrs Figure 1
(a) Effects of armepavine on collagen deposition by HSC-T6 cells after TNF-α stimulation for 24 hrs. Collagen 
deposition by HSC-T6 cells was quantified by Sircol collagen assay (n = 3). *p < 0.05 for TNF-α alone vs. Control; #p < 0.05 for 
TNF-α + armepavine vs. TNF-α alone. (b) Armepavine reduced the protein expression of α-SMA induced by 
lipopolysaccharide (LPS, 1 μg/ml) in HSC-T6 cells for 24 hrs. Representative results from three independent experi-
ments are shown here, with N-acetylcysteine (NAC) as a positive control. *p < 0.05 for LPS alone vs. Control; #p < 0.05 for 
LPS + armepavine or NAC vs. LPS alone.
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cysteine (NAC, 5 mM, a positive-control inhibitor) and
Arm (1, 3 and 10 μM) reduced TNF-α-stimulated α-SMA
secretion (to 101 ± 8% for NAC, 160 ± 4%, 127 ± 4% and
106 ± 8%, respectively, of control level) in HSCs.
LPS (1 μg/ml) also stimulated α-SMA secretion (to 174 ±
37% of control level) in HSC-T6 cells. Both NAC and Arm
(1 - 10 μM) reduced LPS-stimulated α-SMA secretion in
HSCs (Fig. 1b). Arm at the concentration range of 1-10
μM did not affect HSC cell viability in the MTT assay. Cell
viability for Arm at 10 μM was 98 ± 4% of controls and
not different from controls.
Effects of Arm on TNF-α-induced AP-1 and NFκB luciferase reporter 
gene assays in HSCs
HSC-T6 cells were transfected with pAP-1-Luc plasmid,
which contains the AP-1-responsive region followed by
the firefly luciferase gene. After exogenously adding luci-
ferin to cell lysates, the luciferase-luciferin reactions gen-
erated luminescence with high sensitivity and could be
measured. The luciferase levels of AP-1 in HSCs under
TNF-α (10 ng/ml) were increased to 362 ± 36% of control
level, which were concentration-dependently reduced by
Arm (1, 3, and 10 μM, to 330 ± 49%, 274 ± 47% and 184
± 13%, respectively, of control level, with significant dif-
ference at 10 μM). Arm (3 and 10 μM) also significantly
attenuated LPS-stiumulated AP-1 luciferase levels (from
720 ± 43% to 360 ± 50% and 240 ± 115%, respectively, of
control level) in HSCs. Similarly, TNF-α (10 ng/ml) sig-
nificantly increased cytosolic IκBα phosphorylation and
the NFκB (p65) protein amount in nuclear extracts of
cells, indicative of nuclear translocation of active NFκB
subunit. Both cytosolic IκBα phosphorylation and
nuclear NFκB (p65) protein amount were concentration-
dependently reduced by Arm (1 - 10 μM) (Fig. 2a). More-
over, Arm (1 - 10 μM) concentration-dependently
reduced TNF-α-induced NFκB luciferase levels in HSCs
(Fig. 2b).
Effects of Arm on TNF-α-stimulated MAPK phosphorylations
The phosphorylations of MAP kinases are involved in
HSC activation [1,4]. TNF-α-induced MAPK (p38, ERK1/
2, and JNK) phosphorylations were analyzed by Western
blot analyses of cell lysates of HSCs. As shown in Figure
3a, stimulation with TNF-α for up to 60 min significantly
increased the levels of phosphorylated p38, ERK1/2, and
JNK as compared to the unstimulated control. Peak ERK1/
2, p38, and JNK phosphorylations occurred at 15, 30, and
60 min., respectively, and Arm (10 μM) attenuated all
these phosphorylations.
Effects of Arm on mRNA expression levels of iNOS, collagen 1α2, 
TIMP-1 and α-SMA genes in HSCs
Figure 3b shows that TNF-α (10 ng/ml) stimulated mRNA
expression levels of iNOS, collagen 1α2, TIMP-1 and α-
SMA genes in HSC-T6 cells, as shown by quantitative real-
time PCR analysis of gene transcripts. Arm (1 - 10 μM)
concentration-dependently reduced TNF-α-induced tran-
scriptions of these 4 fibrosis-related genes.
In vivo effects of Arm on BDL rats
General features
The body weight of BDL rats was significantly lower than
that of sham rats. BDL rats also displayed a sickened
appearance, including less vigorous movements and less-
smooth fir. The body weight of BDL rats was increased in
the rats treated with either the low or high dose of Arm
(Table 1). BDL rats showed an increase in liver weight
(29.2 ± 0.4 vs. 19.5 ± 0.8 g, p < 0.05) compared with sham
rats, a sign of hepatomegaly. Both Arm and silymarin
treatment mildly decreased the liver weight in BDL rats
(Table 1).
Plasma biochemistry
BDL rats showed significantly higher plasma ALT (756 ±
19 vs. 76 ± 5 U/ml, p < 0.01) and AST (168 ± 21 vs. 43 ± 2
U/ml, p < 0.01) levels compared with sham rats, indicat-
ing hepatic injury. Levels of both ALT and AST in BDL rats
were significantly decreased by treatment of low-dose- or
high-dose-Arm and silymarin, suggesting that Arm and
silymarin ameliorated hepatic injury in BDL rats (Table
1).
Histological examination
Histological examination of livers from BDL rats revealed
the following changes: progressive increase and expansion
of fibrous septa and loss of hepatocytes, compared with
control rats. Collagen fibers, as stained by Sirius-red, were
distinctly deposited in the liver of BDL rats. Treatment
with either Arm or silymarin decreased collagen deposi-
tion (Fig. 4). Confocal microscopy of double staining for
α-SMA (red) and NFκB (green) also indicates that the α-
SMA-positive cells with NFκB nuclear translocation were
reduced with the high and low doses of Arm, and with
silymarin (figures not shown). As shown in Table 1, BDL
rats showed significantly higher fibrosis scores than sham
rats. Fibrosis scores of livers from BDL rats were signifi-
cantly reduced by treatment of Arm or silymarin (Table 1).
The fibrosis scores were reduced by 47% and 24% with
the high and low doses of Arm, respectively, and by 41%
with silymarin. Hepatocyte necrosis scores in the livers
from BDL rats were significantly reduced in rats treated
with the high and low doses of Arm, and silymarin (Table
1), in line with amelioration of hepatic injury as indicated
by plasma ALT and AST profiles. The hepatocyte necrosis
scores were reduced by 57% and 68% with the high and
low doses of Arm, respectively, and by 75% with sily-
marin. The possibility of adverse effects of high-dose Arm
remains to be clarified in future studies.Journal of Biomedical Science 2009, 16:78 http://www.jbiomedsci.com/content/16/1/78
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(a) Effects of armepavine on TNF-α-induced IκBα phosphorylation in the cytoplasmic extract and translocation of NFκB in the  nuclear extract of HSC-T6 cells for 6 hrs, with PCNA and α-tubulin as internal controls Figure 2
(a) Effects of armepavine on TNF-α-induced IκBα phosphorylation in the cytoplasmic extract and transloca-
tion of NFκB in the nuclear extract of HSC-T6 cells for 6 hrs, with PCNA and α-tubulin as internal controls. (b) 
Effects of armepavine on TNF-α-induced NFκB transcriptional activity using luciferase reporter gene assay in 
HSC-T6 cells for 6 hrs, with N-acetylcysteine (NAC) as a positive control. Representative results from three inde-
pendent experiments are shown here *p < 0.05 for TNF-α alone vs. Control; #p < 0.05 for TNF-α + armepavine or NAC vs. 
TNF-α alone.
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(a) Effects of armepavine on TNF-α-induced ERK1/2, p38 and JNK 1/2 phosphorylation levels in HSC-T6 cells Figure 3
(a) Effects of armepavine on TNF-α-induced ERK1/2, p38 and JNK 1/2 phosphorylation levels in HSC-T6 cells. 
HSC-T6 cells were treated with TNF-α for 0-120 minutes. Representative results from three independent experiments are 
shown here. #p < 0.05 for phosphorylation of JNK 1/2 induced by TNF-α + armepavine vs. TNF-α alone at the same time 
point; †p < 0.05 for phosphorylation of ERK 1/2 induced by TNF-α + armepavine vs. TNF-α alone at the same time point; *p < 
0.05 for phosphorylation of p38 induced by TNF-α + armepavine vs. TNF-α alone at the same time point. (b) Quantitative 
real-time PCR analysis for the expressions of iNOS, procollagen type I (Col 1α2), α-SMA and TIMP-1 genes in 
HSC-T6 cells treated with TNF-α and armepavine for 24 hrs. Representative results from three independent experi-
ments are shown here, with N-acetylcysteine (NAC) as a positive control. *p < 0.05 for TNF-α alone vs. Control; #p < 0.05 for 
TNF-α + (S)-armepavine or NAC vs. TNF-α alone.
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Hepatic collagen content and α-SMA expression
Hepatic collagen levels were significantly increased in
BDL rats compared with control rats (6.63 ± 0.31 vs. 3.42
± 0.59 mg/g liver weight, p < 0.01), suggesting abundant
accumulation of collagen in the liver of BDL rats. Hepatic
collagen levels were significantly decreased by high-dose
Arm (4.38 ± 0.33 mg/g, p < 0.01), and silymarin (5.36 ±
0.12 mg/g, p < 0.05), suggesting that Arm and silymarin
ameliorated hepatic collagen deposition in BDL rats. α-
SMA protein expression was increased significantly in the
liver tissues of BDL rats compared with control rats, as
detected by Western blot analysis. Treatment with high-
dose Arm or silymarin reduced α-SMA protein expression
significantly (Table 1).
Analysis of transcripts of procollagen I (col 1α2), transforming
growth factor-β 1 (TGF-β1), tissue inhibitor of metalloprotein-
ase-1 (TIMP-1), intercellular adhesion molecule-I (ICAM-1),
iNOS, interleukin (IL)-6 and metallothionein genes
There were significant increases in hepatic mRNA expres-
sions of procollagen I (col 1α2), transforming growth factor-
β1 (TGF-β1), tissue inhibitor of metalloproteinase-1 (TIMP-
1), intercellular adhesion molecule-I (ICAM-1), iNOS, and
interleukin (IL)-6 genes relative to G3PDH  in BDL rats
compared with control rats (Table 2). The mRNA expres-
sion levels of profibrogenic genes in BDL rats were all
attenuated in Arm and silymarin-treated groups, suggest-
ing that fibrosis-related gene transcripts were attenuated
by Arm or silymarin treatment. On the other hand, the
hepatic mRNA expression of metallothionein gene in BDL
rats was significantly reduced compared with control rats.
High-dose Arm and silymarin treatment significantly
increased the hepatic mRNA expression of metallothionein
gene in BDL rats (Table 2).
Discussion
In the present study, we observed in vitro that Arm exerted
in HSC-T6 cells several inhibitory effects, including (a)
attenuation of TNF-α-induced collagen deposition and α-
SMA protein expression, (b) inhibition of TNF-α-induced
NFκB and AP-1 activities, together with IκBα phosphor-
ylation and NFκB p65 nuclear translocation, (c) down-
regulation of mRNA expressions of iNOS, collagen 1α2,
TIMP-1 and α-SMA genes, (d) attenuation of LPS-induced
α-SMA protein expression and AP-1 activities, (e) suppres-
sion of TNF-α-induced MAPK (p38, ERK1/2, and JNK)
phosphorylations. Our in vivo study showed Arm exerted
inhibitory effects on hepatic fibrosis in BDL rats, includ-
ing (a) reduction of hepatic fibrosis scores and collagen
contents of livers in BDL rats, (b) attenuation of hepatic
injury in terms of plasma ALT and AST levels, (c) reduc-
tion of hepatic mRNA expression levels of procollagen I (col
1α2), transforming growth factor-β1 (TGF-β1), tissue inhibi-
tor of metalloproteinase-1 (TIMP-1), intercellular adhesion
molecule-I (ICAM-1), iNOS, and interleukin (IL)-6 genes,
and (d) improvement of hepatic mRNA expression level
of metallothionein gene. Overall, there was dose-dependent
in vivo therapeuctic effects of Arm in the (a), (b), (c), and
(d) parameters. To our knowledge, the present study was
the first to demonstrate both in vitro inhibitory effects of
Arm on TNF-α-induced NFκB and AP-1 activities as well
as collagen deposition in a cell line of rat hepatic stellate
cells, and in vivo anti-fibrotic effects of Arm on hepatic
fibrosis in BDL rats.
Activation of NFκB signaling pathways is well docu-
mented to result in enhanced transcription of both iNOS
and ICAM-1 genes [6-8]. We propose that Arm exerted
inhibitory effects primarily on NFκB signaling pathways
in HSCs, and thereby led to its in vitro and in vivo anti-
Table 1: General profiles in sham-operated (SO) and bile-duct-ligated (BDL) rats receiving armepavine (Arm), silymarin (sil) or vehicle 
(0.7% CMC) treatment.
Group SO + BDL + BDL + sil BDL + Arm BDL + Arm
vehicle vehicle (50 mg/kg) (3 mg/kg) (10 mg/kg)
BW (g) 386 ± 22 302 ± 21* 335 ± 17.8*,# 333 ± 16.1*,# 345 ± 22.0*,#
LW (g) 19.5 ± 0.8 29.2 ± 0.4* 27.4 ± 0.1*,# 27.5 ± 1.1*,# 26.3 ± 0.3*,#
ALT (U/L) 76 ± 5.0 756 ± 19* 545 ± 10*,# 536 ± 4 *,# 434 ± 11*,#
AST (U/L) 43 ± 2 168 ± 21* 128 ± 8*,# 127 ± 10*,# 73 ± 9*,##
Collagen
(mg/g liver)
3.42 ± 0.59 6.63 ± 0.31* 5.36 ± 0.12*,# 6.18 ± 0.16* 4.38 ± 0.33*,#
α-SMA/α-tubulin ratio (%) 100 ± 1 182 ± 8* 150 ± 3*,# 173 ± 8* 141 ± 12*,#
Fibrosis score 0 ± 0 2.42 ± 0.20* 1.42 ± 0.20*,# 1.85 ± 0.14*,# 1.28 ± 0.18*,##
Necrosis score 0 ± 0 1.17 ± 0.31** 0.29 ± 0.18*,## 0.38 ± 0.18*,# 0.50 ± 0.22*,#
Note: BDL, bile-duct ligated; BW, body weight; LW, liver weight; ALT, alanine transaminase; AST, aspartate transaminase; collagen content (mg/g 
liver dry mass); protein expression of -SMA (expressed as -SMA/-tubulin ratio) in the cytoplasmic extract of liver tissues in Western blot analysis, 
with sham-operated group set as 100%; fibrosis and necrosis scores. Data are expressed as the mean ± SEM. The number of rats in each group is 6. 
*p < 0.05 vs. sham operated group; **p < 0.01 vs. sham operated group; #p < 0.05 vs. BDL group; ##p < 0.01 vs. BDL group.Journal of Biomedical Science 2009, 16:78 http://www.jbiomedsci.com/content/16/1/78
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fibrogenic effects. In the Arm-treated BDL rats, the
number of α-SMA-positive cells was significantly
decreased. Overall, treatments with Arm (10 mg/kg)
yielded better therapeutic benefits than silymarin (50 mg/
kg) in terms of reductions in plasma AST and ALT activi-
ties, hepatic collagen contents, and fibrosis-related mRNA
expressions of TGF-β1, collagen Iα2, iNOS, ICAM-1, and
IL-6  genes. Improvement of hepatic mRNA expression
level of metallothionein gene was also better achieved in
BDL rats receiving Arm than silymarin treatment.
In our in vitro studies, we used N-acetylcysteine (NAC) for
comparison with Arm as NAC has been known to inhibit
TNFα-induced NFκB activity in HSCs [22] and T lym-
phocytes [31]. Silymarin, an extract from milk thistle
(Silybum marianum) was included in the in vivo study for
comparison with Arm, as it has a long history of usage by
patients with liver diseases [32,33] and has been reported
in the literature to exert anti-fibrotic effects in bile-duct-
obstructed and DMN-intoxicated rats [20,34,35]. The dos-
age of silymarin (50 mg/kg) was chosen as our previous
studies have demonstrated its in vivo anti-fibrotic effects
[20-22].
Histological examination of liver sections in control and bile-duct-ligated (BDL) rats Figure 4
Histological examination of liver sections in control and bile-duct-ligated (BDL) rats. Representative liver sections 
were obtained from sham-operated rats (a), BDL rats receiving vehicle (b), BDL rats receiving 50 mg/kg silymarin (c), BDL 
rats receiving 3-mg/kg armepavine (d), and BDL rats receiving 10-mg/kg armepavine (e). Sections were stained with Sirius red. 
Scale bar = 200 m.Journal of Biomedical Science 2009, 16:78 http://www.jbiomedsci.com/content/16/1/78
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BDL has been used to produce a reliable experimental
model due to high yield of liver fibrosis [36]. In our pre-
vious studies, we have observed that oral administration
of tetrandrine (1 and 5 mg/kg, bid) for 3 weeks, an alka-
loid isolated from Chinese medicinal herb Stephania
tetrandrine into BDL rats could also ameliorate hepatic
fibrosis [20]. Although Arm doses (3 and 10 mg/kg, bid)
used in the present study were higher than tetrandrine
doses, the percentage reduction in fibrosis scores was also
higher in Arm than tetrandrine (24% vs. 14% for low-
dose regimen and 47% vs. 38% for high-dose regime,
respectively) [20].
Metallothionein is reported to control intracellular redox
status and regulate the activity of NFκB and other redox-
regulated transcription factors [37]. In the literature, it has
been reported that transfection of the metallothionein gene
inhibits TNF-α-induced IκB degradation and suppresses
NFκB-dependent gene expression induced by TNF-α [37].
Moreover, metallothionein gene therapy has been reported
to attenuate hepatic fibrosis induced by carbon tetrachlo-
ride (CCl4) in mice [38]. We also found that addition of
TNF-α to HSC-T6 cells resulted in the reduction of metal-
lothionein gene expression (data not shown). In our previ-
ous study, we have shown that hepatic mRNA expression
of metallothionein was down-regulated in BDL rats com-
pared to sham rats, suggesting potential impairment of an
intracellular mechanism against oxidative stress [20]. In
the present study, we found that down-regulation of
hepatic metallothionein mRNA expression in BDL rats was
partially corrected by high-dose Arm or silymarin treat-
ment. Taken together, in vivo anti-fibrotic effects of Arm
and silymarin were associated with improved metal-
lothionein mRNA expression in BDL rats.
Mitogen-activated protein kinases (MAPKs) are proposed
to play a key role in intracellular signaling cascades in nor-
mal and pathogenetic conditions [39,40]. ERK1/2, JNK,
and p38 are the three major members of MAPKs and
reported to be associated with cellular oxidative stress,
inflammation, proliferation and migration [39,40]. There
are also cross-talks between MAPK and NFκB signaling
pathways in cellular oxidative stress and inflammation
[41]. In our in vitro study, we observed that both MAPK
and NFκB signaling pathways were activated by TNF-α,
which were attenuated by Arm in HSCs. It remains to be
delineated how Arm inhibited TNF-α-induced MAPK and
NFκB signaling cascades, with respect to cross-talks or net-
works and the diverse molecules involved in HSCs.
Although there are as yet no clinically efficacious anti-
fibrotic agents, experimental studies have been unremit-
tingly conducted to assess the potentials of agents target-
ing the reduction of inflammation, inhibition of HSC
activation or proliferation, induction of HSC apoptosis, or
promotion of scar matrix degradation [1-5]. Recently,
there are some interesting reports of plant-derived anti-
fibrotic agents in experimental animals [32,42,43]. Herbs
or their active principles such as Sho-saiko-to [42,44,45],
silymarin [34,35], Inchin-ko-to [46], Salvia miltiorrhiza
[29,47], curcumin [48] and tetrandrine [20,22], etc., have
been shown respectively to reduce the severity of hepatic
fibrosis in treated rats. These experimental studies suggest
the potential of anti-fibrotic agents from herbs.
In summary, our study results showed that Arm exerted
both in vitro and in vivo antifibrotic effects in rats, possibly
through anti-NF-κB activation pathways. And it remains
to be confirmed for its therapeutic benefits in other ani-
mal models (such as carbon tetrachloride or dimethylnit-
rosamine intoxication) of hepatic fibrosis before
proposing its validation of clinical efficacy using rand-
omized controlled trials [1-5].
Table 2: Quantitative real-time PCR analysis for the mRNA expressions in sham-operated (SO) and bile-duct-ligated (BDL) rats 
receiving armepavine (Arm), silymarin (sil) or vehicle (0.7% CMC) treatment
Group SO + BDL + BDL + sil BDL + Arm BDL + Arm
vehicle vehicle (50 mg/kg) (3 mg/kg) (10 mg/kg)
col1α2/GAPDH 1.00 ± 0.44 12.5 ± 0.2* 7.31 ± 0.11*,# 7.45 ± 0.08*,# 5.09 ± 0.23*,#
TGF-β1/GAPDH 1.00 ± 0.81 21.5 ± 0.2* 13.1 ± 0.9*,# 14.5 ± 0.8*,# 7.09 ± 1.72*,#
TIMP-1/GAPDH 1.01 ± 0.84 28.0 ± 2.6* 4.93 ± 1.88*,# 4.36 ± 1.70*,# 3.87 ± 1.59*,#
ICAM-1/GAPDH 1.00 ± 0.20 22.5 ± 0.5* 12.2 ± 0.1*,# 15.5 ± 0.2*,# 7.03 ± 0.35*,#
iNOS/GAPDH 1.00 ± 0.08 7.53 ± 0.17* 5.31 ± 0.09*,# 6.45 ± 0.08*,# 3.09 ± 0.31*,#
IL-6/GAPDH 1.00 ± 0.10 31.5 ± 0.3* 11.3 ± 0.1*,# 10.5 ± 0.1*,# 4.09 ± 0.17*,#
Metallothionein/GAPDH 1.00 ± 0.10 0.34 ± 0.06* 0.56 ± 0.08*,# 0.37 ± 0.10* 0.57 ± 0.05*,#
Note: Quantitative real-time PCR analysis for the expressions of procollagen I (col 12), transforming growth factor-β1 (TGF-β1), tissue inhibitor of 
metalloproteinase-1 (TIMP-1), intercellular adhension molecule-I (ICAM-1), iNOS, interleukin (IL)-6 and metallothionein genes in sham-operated rats and 
BDL rats receiving saline, Arm (3 and 10 mg/kg) or silymarin (50 mg/kg). Data are expressed as the mean ± SEM. The number of rats in each group 
is 6. *p < 0.05 vs. sham operated group; #p < 0.05 vs. BDL group.Journal of Biomedical Science 2009, 16:78 http://www.jbiomedsci.com/content/16/1/78
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